Novo Nordisk acquired Coramitug from Prothena in July 2021, and is now advancing the drug into Phase 3 development for ATTR amyloidosis with cardiomyopathy.
1 report, 1 independent
Updated Aug 6
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Novo Nordisk acquired Coramitug from Prothena in July 2021, and is now advancing the drug into Phase 3 development for ATTR amyloidosis with cardiomyopathy.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Novo Nordisk
Danish pharmaceutical company
-
Prothena (Ireland)
company in Dublin, Ireland
Nothing else this week.
Related events
Coverage
Newest first; wire copies grouped- Business WireProthena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy Coramitug is a potential first-in-class amyloid deplete